From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
Sonelokimab (ALX 0761) is a trivalent bispecific nanobody composed of camel derived humanized IL-17Fantibodies, IL-17A/Fantibodies, and serum albuminVHHantibodies. Sonelokimab can prolong the plasma half-life by binding to human serum albumin. Sonelokimab can be used for research on rheumatoid arthritis and psoriasis .
Bovine Serum Albumin, Acetylated (Ac-BSA) is a polypeptide of known structure with strong antigenicity. Bovine Serum Albumin, Acetylated produced a significant immune response, validating the accuracy and reliability of the experimental method. Bovine Serum Albumin, Acetylated can be used as a positive control substance in ELISA or WB experiments, and can be used in experiments with acetylated lysine monoclonal or polyclonal antibodies. Bovine Serum Albumin, Acetylated also improves encapsulation efficiency at low concentrations of PLGA, a polymer for biopharmaceutical delivery with biocompatibility, degradability, and controlled release properties .
Gefurulimab (ALXN-1720) is a high-affinity antibody inhibitor targeting complement protein C5, which can specifically bind to C5 and inhibit its cleavage into C5a and C5b. Gefurulimab can block the activation of the terminal complement pathway and reduce inflammatory damage. Gefurulimab can effectively reduce the formation of membrane attack complex (MAC) and has good pharmacokinetic properties. Gefurulimab can be used to study kidney and autoimmune diseases related to abnormal activation of the complement system, such as IgA nephropathy, lupus nephritis, and myasthenia gravis .
Vobarilizumab (ALX-0061) is a humanized bispecific anti-IL-6R and anti-human serum albumin (ALB) monoclonal antibody (mAb) (Kd: 0.19 pM). Vobarilizumab consists of an anti-IL-6R domain and an anti-human serum albumin domain. Vobarilizumab can be used in the research of inflammatory autoimmune diseases, such as rheumatoid arthritis .
Isecarosmab (M-6495) is an anti-ADAMTS monoclonal antibody (mAb) with a KD value of 3.65 pM. Isecarosmab has chondroprotective and anti-inflammatory activities. Isecarosmab can bind albumin to extend plasma half-life .
Ozoralizumab (ATN-103) is an anti-TNFα humanized antibody. Ozoralizumab is a humanized trivalent nanobody compound that consists of two anti-human TNFα nanobodies and an anti-human serum albumin (HSA) nanobody. Ozoralizumab can be used in research of arthritis .
NP-BSA (4-Hydroxy-3-nitrophenylacetyl-bovine serum albumin) is an antigen-adjuvant conjugate of 4-Hydroxy-3-nitrophenylacetyl (NP) conjugated to bovine serum albumin (BSA), which is an immune complex. By conjugating antigens to protein adjuvants, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and can enhance cross-presentation and the generation of antigen-specific T cells .
Derlotuximab is a CHO-expressed, scFv-Fc (huIgG1) type chimeric antibody that targets Histone H1. The predicted molecular weight (MW) of Derlotuximab is 145.1 kDa. The isotype control for Derlotuximab can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Methamphetamine-BSA is a protein consists of Methamphetamine and Bovine Serum Albumin (BSA). Methamphetamine-BSA is an antigen to generate specific antibodies for the detection of Methamphetamine in biological samples .
Cholyglycine/BSA is a conjugate of Cholyglycine and Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the production of antigen-specific T cells.
Marijuana/BSA is the antigen-adjuvant conjugate of Marijuana and Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or destroy major epitopes, and it can enhance cross-presentation and the production of antigen-specific T cells.
PROMETON/BSA is an antigen-adjuvant conjugate formed by the coupling of PROMETON with bovine serum albumin (BSA). By coupling the antigen to the protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the production of antigen-specific T cells.
Angiotensin I/BSA is an antigen-adjuvant conjugate of Angiotensin I and bovine serum albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
Phosphotyrosine/BSA is an antigen-adjuvant conjugate formed by coupling Phosphotyrosine with Bovine Serum Albumin (BSA). By conjugating the antigen with protein adjuvants, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
Diethylstilbestrol/BSA is a conjugate of Diethylstilbestrol (HY-14598) and Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the production of antigen-specific T cells.
COT/BSA is the antigen-adjuvant conjugate of COT (cyclooctatetraene) and Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes and can enhance cross-presentation and the generation of antigen-specific T cells.
Digoxin/BSA is an antigen-adjuvant conjugate of Digoxin (HY-B1049) and Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
Isoniazid/BSA is an antigen-adjuvant conjugate of Isoniazid (HY-B0329) and Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
BZO/BSA is an antigen-adjuvant conjugate formed by the coupling of BZO (benzodiazepine) with bovine serum albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the production of antigen-specific T cells.
Clenbuterol/BSA is an antigen-adjuvant conjugate of Clenbuterol (HY-B1615) and Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, it can enhance the production of antigen-specific antibodies in vaccine models. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
DHT/BSA is an antigen-adjuvant conjugate formed by the coupling of DHT (dihydrotestosterone) and bovine serum albumin (BSA). By conjugating the antigen with the protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
SEM/BSA is an antigen-adjuvant conjugate formed by the conjugation of SEM (furanesalin) with bovine serum albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
Furazolidone/BSA is the antigen-adjuvant conjugate of Furazolidone (HY-B1336) and bovine serum albumin (BSA). By conjugating the antigen with the protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt the major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
Angiotensin II/BSA is an antigen-adjuvant conjugate formed by the coupling of Angiotensin II with bovine serum albumin (BSA). By coupling the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
Metronidazole/BSA is an antigen-adjuvant conjugate of Metronidazole (HY-B0318) and Bovine Serum Albumin (BSA). By conjugating the antigen with the protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the production of antigen-specific T cells.
AHD/BSA is the antigen-adjuvant conjugate of AHD (furan-2-carboxylic acid) and Bovine Serum Albumin (BSA). By conjugating the antigen with the protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or destroy the main epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
5-MethylCytosine/BSA is a conjugate of 5-MethylCytosine (HY-W008091) and Bovine Serum Albumin (BSA). By conjugating the antigen with the protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or destroy key epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
Chloramphenicol/BSA is the antigen-adjuvant conjugate formed by the coupling of Chloramphenicol (HY-B0239) with Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
Tetracycline/BSA is an antigen-adjuvant conjugate formed by the conjugation of Tetracycline (HY-A0107) with Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it enhances cross-presentation and the generation of antigen-specific T cells.
Oxytetracycline/BSA is an antigen-adjuvant conjugate formed by the coupling of Oxytetracycline (HY-B0275) with Bovine Serum Albumin (BSA). By conjugating the antigen with the protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the production of antigen-specific T cells.
3-Nitrotyrosine/BSA is an antigen-adjuvant conjugate formed by the conjugation of 3-Nitrotyrosine with Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it enhances cross-presentation and the generation of antigen-specific T cells.
Tacrolimus/BSA is the antigen-adjuvant conjugate formed by the conjugation of Tacrolimus (HY-13756) with Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, it can enhance the production of antigen-specific antibodies in vaccine models. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
Ractopamine/BSA is an antigen-adjuvant conjugate formed by the conjugation of Ractopamine (HY-113781) with Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
Estradiol/BSA is the antigen-adjuvant conjugate formed by the coupling of Estradiol (HY-B0141) with Bovine Serum Albumin (BSA). By coupling the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
Sulfadiazine/BSA is an antigen-adjuvant conjugate formed by the conjugation of Sulfadiazine (HY-B0273) with Bovine Serum Albumin (BSA). By conjugating the antigen with the protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
T3/BSA is an antigen-adjuvant conjugate of T3 (thyroid hormone) and bovine serum albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
GABA/BSA is an antigen-adjuvant conjugate formed by the coupling of GABA (γ-aminobutyric acid) with Bovine Serum Albumin (BSA). By coupling the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
Sudan I/BSA is the antigen-adjuvant conjugate formed by Sudan I (HY-D0024) and Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
Gastrin(1-17)/BSA is an antigen-adjuvant conjugate formed by the coupling of Gastrin(1-17) and Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or destroy major epitopes, and it can enhance cross-presentation and the production of antigen-specific T cells.
Prostaglandin F2a/BSA is an antigen-adjuvant conjugate formed by the conjugation of Prostaglandin F2a with Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes and can enhance cross-presentation as well as the generation of antigen-specific T cells.
4,4'-Sulfonyldiphenol/BSA is the antigen-adjuvant conjugate of 4,4'-Sulfonyldiphenol (HY-W011927) and Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the production of antigen-specific T cells.
1-(2-Aminoethyl)-1H-pyrazol-4-ylphosphonic acid linker/BSA is the conjugate of 1-(2-Aminoethyl)-1H-pyrazol-4-ylphosphonic acid linker and bovine serum albumin (BSA). By conjugating the antigen with a protein adjuvant, it enhances the production of antigen-specific antibodies in vaccine models. The conjugate does not affect protein folding or disrupt key epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
Bovine Serum Albumin, Acetylated (Ac-BSA) is a polypeptide of known structure with strong antigenicity. Bovine Serum Albumin, Acetylated produced a significant immune response, validating the accuracy and reliability of the experimental method. Bovine Serum Albumin, Acetylated can be used as a positive control substance in ELISA or WB experiments, and can be used in experiments with acetylated lysine monoclonal or polyclonal antibodies. Bovine Serum Albumin, Acetylated also improves encapsulation efficiency at low concentrations of PLGA, a polymer for biopharmaceutical delivery with biocompatibility, degradability, and controlled release properties .
NP-BSA (4-Hydroxy-3-nitrophenylacetyl-bovine serum albumin) is an antigen-adjuvant conjugate of 4-Hydroxy-3-nitrophenylacetyl (NP) conjugated to bovine serum albumin (BSA), which is an immune complex. By conjugating antigens to protein adjuvants, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and can enhance cross-presentation and the generation of antigen-specific T cells .
Phosphotyrosine/BSA is an antigen-adjuvant conjugate formed by coupling Phosphotyrosine with Bovine Serum Albumin (BSA). By conjugating the antigen with protein adjuvants, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
Methamphetamine-BSA is a protein consists of Methamphetamine and Bovine Serum Albumin (BSA). Methamphetamine-BSA is an antigen to generate specific antibodies for the detection of Methamphetamine in biological samples .
Cholyglycine/BSA is a conjugate of Cholyglycine and Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the production of antigen-specific T cells.
Marijuana/BSA is the antigen-adjuvant conjugate of Marijuana and Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or destroy major epitopes, and it can enhance cross-presentation and the production of antigen-specific T cells.
PROMETON/BSA is an antigen-adjuvant conjugate formed by the coupling of PROMETON with bovine serum albumin (BSA). By coupling the antigen to the protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the production of antigen-specific T cells.
Angiotensin I/BSA is an antigen-adjuvant conjugate of Angiotensin I and bovine serum albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
Diethylstilbestrol/BSA is a conjugate of Diethylstilbestrol (HY-14598) and Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the production of antigen-specific T cells.
COT/BSA is the antigen-adjuvant conjugate of COT (cyclooctatetraene) and Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes and can enhance cross-presentation and the generation of antigen-specific T cells.
Digoxin/BSA is an antigen-adjuvant conjugate of Digoxin (HY-B1049) and Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
Isoniazid/BSA is an antigen-adjuvant conjugate of Isoniazid (HY-B0329) and Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
BZO/BSA is an antigen-adjuvant conjugate formed by the coupling of BZO (benzodiazepine) with bovine serum albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the production of antigen-specific T cells.
Clenbuterol/BSA is an antigen-adjuvant conjugate of Clenbuterol (HY-B1615) and Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, it can enhance the production of antigen-specific antibodies in vaccine models. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
DHT/BSA is an antigen-adjuvant conjugate formed by the coupling of DHT (dihydrotestosterone) and bovine serum albumin (BSA). By conjugating the antigen with the protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
SEM/BSA is an antigen-adjuvant conjugate formed by the conjugation of SEM (furanesalin) with bovine serum albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
Furazolidone/BSA is the antigen-adjuvant conjugate of Furazolidone (HY-B1336) and bovine serum albumin (BSA). By conjugating the antigen with the protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt the major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
Angiotensin II/BSA is an antigen-adjuvant conjugate formed by the coupling of Angiotensin II with bovine serum albumin (BSA). By coupling the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
Metronidazole/BSA is an antigen-adjuvant conjugate of Metronidazole (HY-B0318) and Bovine Serum Albumin (BSA). By conjugating the antigen with the protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the production of antigen-specific T cells.
AHD/BSA is the antigen-adjuvant conjugate of AHD (furan-2-carboxylic acid) and Bovine Serum Albumin (BSA). By conjugating the antigen with the protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or destroy the main epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
5-MethylCytosine/BSA is a conjugate of 5-MethylCytosine (HY-W008091) and Bovine Serum Albumin (BSA). By conjugating the antigen with the protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or destroy key epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
Chloramphenicol/BSA is the antigen-adjuvant conjugate formed by the coupling of Chloramphenicol (HY-B0239) with Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
Tetracycline/BSA is an antigen-adjuvant conjugate formed by the conjugation of Tetracycline (HY-A0107) with Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it enhances cross-presentation and the generation of antigen-specific T cells.
Oxytetracycline/BSA is an antigen-adjuvant conjugate formed by the coupling of Oxytetracycline (HY-B0275) with Bovine Serum Albumin (BSA). By conjugating the antigen with the protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the production of antigen-specific T cells.
3-Nitrotyrosine/BSA is an antigen-adjuvant conjugate formed by the conjugation of 3-Nitrotyrosine with Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it enhances cross-presentation and the generation of antigen-specific T cells.
Tacrolimus/BSA is the antigen-adjuvant conjugate formed by the conjugation of Tacrolimus (HY-13756) with Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, it can enhance the production of antigen-specific antibodies in vaccine models. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
Ractopamine/BSA is an antigen-adjuvant conjugate formed by the conjugation of Ractopamine (HY-113781) with Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
Estradiol/BSA is the antigen-adjuvant conjugate formed by the coupling of Estradiol (HY-B0141) with Bovine Serum Albumin (BSA). By coupling the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
Sulfadiazine/BSA is an antigen-adjuvant conjugate formed by the conjugation of Sulfadiazine (HY-B0273) with Bovine Serum Albumin (BSA). By conjugating the antigen with the protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
T3/BSA is an antigen-adjuvant conjugate of T3 (thyroid hormone) and bovine serum albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
GABA/BSA is an antigen-adjuvant conjugate formed by the coupling of GABA (γ-aminobutyric acid) with Bovine Serum Albumin (BSA). By coupling the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
Sudan I/BSA is the antigen-adjuvant conjugate formed by Sudan I (HY-D0024) and Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
Gastrin(1-17)/BSA is an antigen-adjuvant conjugate formed by the coupling of Gastrin(1-17) and Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or destroy major epitopes, and it can enhance cross-presentation and the production of antigen-specific T cells.
Prostaglandin F2a/BSA is an antigen-adjuvant conjugate formed by the conjugation of Prostaglandin F2a with Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes and can enhance cross-presentation as well as the generation of antigen-specific T cells.
4,4'-Sulfonyldiphenol/BSA is the antigen-adjuvant conjugate of 4,4'-Sulfonyldiphenol (HY-W011927) and Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the production of antigen-specific T cells.
1-(2-Aminoethyl)-1H-pyrazol-4-ylphosphonic acid linker/BSA is the conjugate of 1-(2-Aminoethyl)-1H-pyrazol-4-ylphosphonic acid linker and bovine serum albumin (BSA). By conjugating the antigen with a protein adjuvant, it enhances the production of antigen-specific antibodies in vaccine models. The conjugate does not affect protein folding or disrupt key epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
SA-21 is a 21-amino acid polymer peptide (Ac-RLIEDICLPRWGCLWEDD-NH2) that binds to ligands of urokinase-type plasminogen activator, Fab antibody fragments, and small proteins. SA-21 can be used to purify albumin (Ki=1.9 μM) .
Sonelokimab (ALX 0761) is a trivalent bispecific nanobody composed of camel derived humanized IL-17Fantibodies, IL-17A/Fantibodies, and serum albuminVHHantibodies. Sonelokimab can prolong the plasma half-life by binding to human serum albumin. Sonelokimab can be used for research on rheumatoid arthritis and psoriasis .
Gefurulimab (ALXN-1720) is a high-affinity antibody inhibitor targeting complement protein C5, which can specifically bind to C5 and inhibit its cleavage into C5a and C5b. Gefurulimab can block the activation of the terminal complement pathway and reduce inflammatory damage. Gefurulimab can effectively reduce the formation of membrane attack complex (MAC) and has good pharmacokinetic properties. Gefurulimab can be used to study kidney and autoimmune diseases related to abnormal activation of the complement system, such as IgA nephropathy, lupus nephritis, and myasthenia gravis .
Vobarilizumab (ALX-0061) is a humanized bispecific anti-IL-6R and anti-human serum albumin (ALB) monoclonal antibody (mAb) (Kd: 0.19 pM). Vobarilizumab consists of an anti-IL-6R domain and an anti-human serum albumin domain. Vobarilizumab can be used in the research of inflammatory autoimmune diseases, such as rheumatoid arthritis .
Isecarosmab (M-6495) is an anti-ADAMTS monoclonal antibody (mAb) with a KD value of 3.65 pM. Isecarosmab has chondroprotective and anti-inflammatory activities. Isecarosmab can bind albumin to extend plasma half-life .
Ozoralizumab (ATN-103) is an anti-TNFα humanized antibody. Ozoralizumab is a humanized trivalent nanobody compound that consists of two anti-human TNFα nanobodies and an anti-human serum albumin (HSA) nanobody. Ozoralizumab can be used in research of arthritis .
Derlotuximab is a CHO-expressed, scFv-Fc (huIgG1) type chimeric antibody that targets Histone H1. The predicted molecular weight (MW) of Derlotuximab is 145.1 kDa. The isotype control for Derlotuximab can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Albumin Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 69 kDa, targeting to Albumin. It can be used for WB,IHC-P assays with tag free, in the background of Human, Mouse.
BSA Antibodyis a non-conjugated and mouse origined monoclonal antibody about 66 kDa, targeting to BSA. It can be used for WB,ELISA assays with tag free, in the background of Cow.
ALB; ALBU_HUMAN; Albumin (32 AA); Albumin (AA 34); Albumin; AnAlbuminemia; BisAlbuminemia; Cell growth inhibiting protein 42; DKFZp779N1935; DysAlbuminemic hyperthyroxinemia; Growth inhibiting protein 20; HSA; Hyperthyroxinemia dysAlbuminemic; Serum Albumin.
ELISA
Human
Human Serum Albumin Antibody (YA984) is a mouse-derived non-conjugated IgG1 antibody (Clone NO.: YA984), targeting Human Serum Albumin. Human Serum Albumin Antibody (YA984) can be used for ELISA experiment in human background.
Albumin Antibody (YA6047) is a rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Albumin. It can be applicated for WB, IHC-P, ICC/IF, IP, ELISA assays, in the background of human, mouse, rat.
Albumin Antibody (YA6424) is a mouse-derived and non-conjugated IgG monoclonal antibody, targeting to Albumin. It can be applicated for WB assays, in the background of cow, goat.
Bovine Serum Albumin Antibody (YA5428) is a mouse-derived and non-conjugated monoclonal antibody, targeting to Bovine Serum Albumin. It can be applicated for WB assays, in the background of cow.
ALB; ALBU_HUMAN; Albumin (32 AA); Albumin (AA 34); Albumin; AnAlbuminemia; BisAlbuminemia; Cell growth inhibiting protein 42; DKFZp779N1935; DysAlbuminemic hyperthyroxinemia; Growth inhibiting protein 20; HSA; Hyperthyroxinemia dysAlbuminemic; Serum Albumin.
WB, ELISA
Human
Human Serum Albumin Antibody (YA985) is a mouse-derived non-conjugated IgG1 antibody (Clone NO.: YA985), targeting Human Serum Albumin, with a predicted molecular weight of 69 kDa (observed band size: 69 kDa). Human Serum Albumin Antibody (YA985) can be used for WB, ELISA experiment in human background.
Product Comparison
Compare
Clear All
Compare Products
Products
In-stock
-
+
Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample
YesNo
Size
* This product has been "discontinued".
Optimized version of product available:
/
In-stock
-
+
Add to Cart
Get quote
Inquiry Online
Your information is safe with us. * Required Fields.
